Inflammation theories in psychotic disorders: A critical review

Infectious Disorders - Drug Targets

Volumn 13, Issue 1, 2013, Pages 59-70

  Suvisaari, Jaana ^a   Mantere, Outi ^a,b  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Autoimmunity; Bipolar I disorder; Infections; Inflammation; Microglia; Psychotic disorders; Schizophrenia

Indexed keywords

CELECOXIB; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; MINOCYCLINE; PEROSPIRONE; POLYUNSATURATED FATTY ACID; PRASTERONE; PREGNENOLONE; QUETIAPINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; ZIPRASIDONE;

ADAPTIVE IMMUNITY; AUTOIMMUNITY; BIPOLAR I DISORDER; BRAIN DEVELOPMENT; BRAIN FUNCTION; CARDIOVASCULAR DISEASE; COMORBIDITY; GENETIC RISK; HIGH RISK PATIENT; HUMAN; IMMUNE SYSTEM; IMMUNITY; INFLAMMATION; INTRAUTERINE INFECTION; LIFESTYLE; META ANALYSIS (TOPIC); METABOLIC DISORDER; MICROGLIA; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; PRENATAL DEVELOPMENT; PSYCHOSIS; REVIEW; SCHIZOPHRENIA;

ADAPTIVE IMMUNITY; ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNITY; BIPOLAR DISORDER; BRAIN; HUMANS; IMMUNE SYSTEM; INFECTION; MICROGLIA; NEUROGENESIS; NEURONS; NEUROPROTECTIVE AGENTS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 84878769151     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/18715265112129990032     Document Type: Review

References (155)

1. Drexhage, R.C.; Knijff, E.M.; Padmos, R.C.; van der Heul-Nieuwenhuijzen, L.; Beumer, W.; Versnel, M.A.; Drexhage, H.A. The mononuclear phagocyte system and its cytokine networks in schizophrenia and bipolar disorder. Expert Rev. Neurother., 2010, 10, 59-76.
2. Padmos, R.C.; Hillegers, M.H.; Knijff, E.M.; Vonk, R.; Bouvy, A.; Staal, F.J.; de Ridder, D.; Kupka, R.W.; Nolen, W.A.; Drexhage, H.A. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch. Gen. Psychiatry, 2008, 65(4), 395-407.
3. Drexhage, R.C.; van der Heul-Nieuwenhuijsen, L.; Padmos, R.C.; van Beveren, N.; Cohen, D.; Versnel, M.A.; Nolen, W.A.; Drexhage, H.A. Inflammatory gene expression in monocytes of patients with schizophrenia: overlap and difference with bipolar disorder. A study in naturalistically treated patients. Int. J. Neuropsychopharmacol., 2010, 13, 1369-1381.
4. Drexhage, R.C.; Hoogenboezem, T.A.; Cohen, D.; Versnel, M.A.; Nolen, W.A.; van Beveren, N.J.; Drexhage, H.A. An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro-and anti-inflammatory forces. Int. J. Neuropsychopharmacol., 2011, 14, 746-755.
5. Suvisaari, J.; Loo, B.-M.; Saarni, S.E.; Haukka, J.; Perälä, J.; Saarni, S.I.; Viertiö, S.; Partti, K.; Lönnqvist, J.; Jula, A. Inflammation in psychotic disorders: a population-based study. Psychiatry Res., 2011, 189, 305-311.
6. Miller, B.J.; Culpepper, N.; Rapaport, M.H.; Buckley, P. Prenatal inflammation and neurodevelopment in schizophrenia: A review of human studies. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2012 [Epub ahead of print]
7. Chaplin, D.D. Overview of the immune response. J. Allergy Clin. Immunology, 2010, 125, S3-23.
8. Malek, T.R.; Bayer, A.L. Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol., 2004, 4(9), 665-74.
9. Buckner, J.H. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in hfuman autoimmune diseases. Nat. Rev. Immunol., 2010, 10(12), 849-859.
10. Deverman, B.E.; Patterson, P.H. Cytokines and CNS development. Neuron, 2009, 64(1), 61-78.
11. Carpentier, P.A.; Palmer, T.D. Immune influence on adult neural stem cell regulation and function. Neuron, 2009, 64(1), 79-92.
12. Boulanger, L.M. Immune proteins in brain development and synaptic plasticity. Neuron, 2009, 64, 93-109.
13. Bauer, S. Cytokine control of adult neural stem cells. Chronic versus acute exposure. Ann. N. Y. Acad. Sci., 2009, 1153, 48-56.
14. de Araujo, E.G.; da Silva, G.M.; Dos Santos, A.A. Neuronal cell survival: the role of interleukins. Ann. N. Y. Acad. Sci., 2009, 1153, 57-64.
15. Dantzer, R.; O'Connor, J.C.; Freund, G.G.; Johnson, R.W.; Kelley, K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci., 2008, 9, 46-57.
16. Miller, A.H.; Maletic, V.; Raison, C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry, 2009, 65, 732-741.
17. Kempermann, G. Seven principles in the regulation of adult neurogenesis. Eur. J. Neurosci., 2011, 33(6), 1018-1024.
18. Ygberg, S.; Nilsson, A. The developing immune system-from foetus to toddler. Acta Paediatr., 2012, 101(2), 120-127.
19. Brown, A.S.; Derkits, E.J. Prenatal infection and schizophrenia: A review of epidemiologic and translational studies. Am. J. Psychiatry, 2010, 167(3), 261-280.
20. Kneeland, R.E.; Fatemi, S.H. Viral infection, inflammation and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2013, 42, 35-48.
21. Buka, S.L.; Tsuang, M.T.; Torrey, E.F.; Klebanoff, M.A.; Wagner, R.L.; Yolken, R.H. Maternal cytokine levels during pregnancy and adult psychosis. Brain Behav. Immun., 2001, 15(4), 411-420.
22. Brown, A.S.; Hooton, J.; Schaefer, C.A.; Zhang, H.; Petkova, E.; Babulas, V.; Perrin, M.; Gorman, J.M.; Susser, E.S. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am. J. Psychiatry, 2004, 161(5), 889-895.
23. Cannon, M.; Jones, P.B.; Murray, R.M. Obstetric complications and schizophrenia: Historical and meta-analytic review. Am. J. Psychiatry, 2002, 159(7), 1080-1092.
24. van Os, J.; Selten, J.P. Prenatal exposure to maternal stress and subsequent schizophrenia. The May 1940 invasion of The Netherlands. Br. J. Psychiatry, 1998, 172, 324-326.
25. Huttunen, M.O.; Niskanen, P. Prenatal loss of father and psychiatric disorders. Arch. Gen. Psychiatry, 1978, 35(4), 429-431.
26. Susser, E.; Neugebauer, R.; Hoek, H.W.; Brown, A.S.; Lin, S.; Labovitz, D.; Gorman, J.M. Schizophrenia after prenatal famine. Further evidence. Arch. Gen. Psychiatry, 1996, 53(1), 25-31.
27. St Clair, D.; Xu, M.; Wang, P.; Yu, Y.; Fang, Y.; Zhang, F.; Zheng, X.; Gu, N.; Feng, G.; Sham, P.; He, L. Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959-1961. JAMA, 2005, 294(5), 557-562.
28. Karlsson, H.; Blomström, A.; Wicks, S., Yang, S.; Yolken, R.H.; Dalman, C. Maternal antibodies to dietary antigens and risk for nonaffective psychosis in offspring. Am. J. Psychiatry, 2012, 169(6), 625-632.
29. Watanabe, Y.; Someya, T.; Nawa, H. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry Clin. Neurosci., 2010, 64(3), 217-230.
30. Faupel-Badger, J.M.; Fichorova, R.N.; Allred, E.N.; Hecht, J.L.; Dammann, O.; Leviton, A.; McElrath, T.F. Cluster analysis of placental inflammatory proteins can distinguish preeclampsia from preterm labor and premature membrane rupture in singleton deliveries less than 28 weeks of gestation. Am. J. Reprod. Immunol., 2011, 66(6), 488-494.
31. Coussons-Read, M.E.; Lobel, M.; Carey, J.C.; Kreither, M.O.; D'Anna, K.; Argys, L.; Ross, R.G.; Brandt, C.; Cole, S. The occurrence of preterm delivery is linked to pregnancy-specific distress and elevated inflammatory markers across gestation. Brain Behav. Immun., 2012, 26(4), 650-659.
32. Coussons-Read, M.E.; Okun, M.L.; Nettles, C.D. Psychosocial stress increases inflammatory markers and alters cytokine production across pregnancy. Brain Behav. Immun., 2007, 21(3), 343-350.
33. Carpentier, P.A.; Dingman, A.L.; Palmer, T.D. Placental TNF-α signaling in illness-induced complications of pregnancy. Am. J. Pathol., 2011, 178(6), 2802-2810.
34. Diamond, B.; Huerta, P.T.; Mina-Osorio, P.; Kowal, C.; Volpe, B.T. Losing your nerves? Maybe it's the antibodies. Nat Rev Immunol., 2009, 9, 449-456.
35. Canti, V.; Castiglioni, M.T.; Rosa, S.; Franchini, S.; Sabbadini, M.G.; Manfredi, A.A.; Rovere-Querini, P. Pregnancy outcomes in patients with systemic autoimmunity. Autoimmunity, 2012, 45, 169-175.
36. Meyer, U.; Feldon, J.; Dammann, O. Schizophrenia and autism: both shared and disorder-specific pathogenesis via perinatal inflammation? Pediatr. Res., 2011, 69, 26R-33R.
37. Ellison-Wright, I.; Bullmore, E. Anatomy of bipolar disorder and schizophrenia: a meta-analysis. Schizophr. Res., 2010, 117(1), 1-12.
38. Cannon, T.D.; Thompson, P.M.; van Erp, T.G.; Toga, A.W.; Poutanen, V.P.; Huttunen, M.; Lönnqvist, J.; Standerskjold-Nordenstam, C.G.; Narr, K.L.; Khaledy, M.; Zoumalan, C.I.; Dail, R.; Kaprio, J. Cortex mapping reveals regionally specific patterns of genetic and disease-specific gray-matter deficits in twins discordant for schizophrenia. Proc. Natl. Acad. Sci. U.S.A., 2002, 99(5), 3228-3233.
39. Kieseppä, T.; van Erp, T.G.; Haukka, J.; Partonen, T.; Cannon, T.D.; Poutanen, V.P.; Kaprio, J.; Lönnqvist, J. Reduced left hemispheric white matter volume in twins with bipolar I disorder. Biol. Psychiatry, 2003, 54(9), 896-905.
40. Bearden, C.E.; van Erp, T.G.; Dutton, R.A.; Boyle, C.; Madsen, S.; Luders, E.; Kieseppä, T.; Tuulio-Henriksson, A.; Huttunen, M.; Partonen, T.; Kaprio, J.; Lönnqvist, J.; Thompson, P.M.; Cannon, T.D. Mapping corpus callosum morphology in twin pairs discordant for bipolar disorder. Cereb. Cortex, 2011, 21(10), 2415-2424.
41. Ziermans, T.B.; Schothorst, P.F.; Schnack, H.G.; Koolschijn, P.C.; Kahn, R.S.; van Engeland, H.; Durston, S. Progressive structural brain changes during development of psychosis. Schizophr. Bull., 2012, 38(3), 519-530.
42. McIntosh, A.M.; Owens, D.C.; Moorhead, W.J.; Whalley, H.C.; Stanfield, A.C.; Hall, J.; Johnstone, E.C.; Lawrie, S.M. Longitudinal volume reductions in people at high genetic risk of schizophrenia as they develop psychosis. Biol. Psychiatry, 2011, 69, 953-958.
43. Andreasen, N.C.; Nopoulos, P.; Magnotta, V.; Pierson, R.; Ziebell, S.; Ho, B.C. Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia. Biol. Psychiatry, 2011, 70(7), 672-679.
44. Schloesser, R.J.; Chen, G.; Manji, H.K. Neurogenesis and neuroenhancement in the pathophysiology and treatment of bipolar disorder. Int. Rev. Neurobiol., 2007, 77, 143-178.
45. Valvezan, A.J.; Klein, P.S. GSK-3 and Wnt signaling in neurogenesis and bipolar disorder. Front. Mol. Neurosci., 2012, 5, 1.
46. Meyer-Lindenberg, A. Neuroimaging and the question of neurodegeneration in schizophrenia. Prog. Neurobiol., 2011, 95(4), 514-516.
47. Monji, A.; Kato, T.; Kanba, S. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin. Neurosci., 2009, 63(3), 257-265.
48. Monji, A.; Kato, T.A.; Mizoguchi, Y.; Horikawa, H.; Seki, Y.; Kasai, M.; Yamauchi, Y.; Yamada, S.; Kanba, S. Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2013, 42, 115-121.
49. Bilbo, S.D.; Schwarz, J.M. Early-life programming of later-life brain and behavior: a critical role for the immune system. Front. Behav. Neurosci., 2009, 3, 14.
50. Schloesser, R.J.; Huang, J.; Klein, P.S.; Manji, H.K. Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology, 2008, 33(1), 110-133.
51. Morrens, J.; Van Den Broeck, W.; Kempermann G. Glial cells in adult neurogenesis. Glia, 2012, 60(2), 159-174.
52. Doorduin J.; de Vries, E.F.; Willemsen, A.T.; de Groot, J.C.; Dierckx, R.A.; Klein, H.C. Neuroinflammation in schizophrenia-related psychosis: a PET study. J. Nucl. Med., 2009, 50(11), 1801-1807.
53. van Berckel, B.N.; Bossong, M.G.; Boellaard, R.; Kloet, R.; Schuitemaker, A.; Caspers, E.; Luurtsema, G.; Windhorst, A.D.; Cahn, W.; Lammertsma, A.A.; Kahn, R.S. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol. Psychiatry, 2008, 64(9), 820-822.
54. Söderlund, J.; Schröder, J.; Nordin, C.; Samuelsson, M.; Walther-Jallow, L.; Karlsson, H.; Erhardt, S.; Engberg, G. Activation of brain interleukin-1beta in schizophrenia. Mol. Psychiatry, 2009, 14(12), 1069-1071.
55. Rothermundt, M.; Falkai, P.; Ponath, G.; Abel, S.; Bürkle, H.; Diedrich, M.; Hetzel, G.; Peters, M.; Siegmund, A.; Pedersen, A.; Maier, W.; Schramm, J.; Suslow, T.; Ohrmann, P.; Arolt, V. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol. Psychiatry, 2004, 9, 897-899.
56. Nikkilä, H.V.; Müller, K.; Ahokas, A.; Miettinen, K.; Rimón, R.; Andersson, L.C. Accumulation of macrophages in the CSF of schizophrenic patients during acute psychotic episodes. Am. J. Psychiatry, 1999, 156(11), 1725-1729.
57. Nikkilä, H.V.; Müller, K.; Ahokas, A.; Rimón, R.; Andersson, L.C. Increased frequency of activated lymphocytes in the cerebrospinal fluid of patients with acute schizophrenia. Schizophr. Res., 2001, 49, 99-105.
58. Miller, B.J.; Buckley, P.; Seabolt, W.; Mellor, A.; Kirkpatrick, B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry, 2011, 70, 663-671.
59. Goldsmith, C.A., Rogers, D.P. The case for autoimmunity in the etiology of schizophrenia. Pharmacotherapy, 2008, 28(6), 730-741.
60. Eaton, W.W.; Pedersen, M.G.; Nielsen, P.R.; Mortensen, P.B. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord., 2010, 12, 638-646.
61. Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am. J. Psychiatry, 2011, 168(12), 1303-1310.
62. Hanly, J.G.; Urowitz, M.B.; Siannis, F.; Farewell, V.; Gordon, C.; Bae, S.C.; Isenberg, D.; Dooley, M.A.; Clarke, A.; Bernatsky, S.; Gladman, D.; Fortin, P.R.; Manzi, S., Steinsson, K.; Bruce, I.N.; Ginzler, E.; Aranow, C.; Wallace, D.J.; Ramsey-Goldman, R.; van Vollenhoven, R.; Sturfelt, G.; Nived, O.; Sanchez-Guerrero, J.; Alarcón, G.S.; Petri, M., Khamashta, M.; Zoma, A., Font, J.; Kalunian, K.; Douglas, J.; Qi, Q.; Thompson, K.; Merrill, J.T.; Systemic Lupus International Collaborating Clinics. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum., 2008, 58, 843-853.
63. Wandinger, K.P.; Saschenbrecker, S.; Stoecker, W.; Dalmau, J. Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis. J. Neuroimmunol., 2011, 231, 86-91.
64. Faust, T.W.; Chang, E.H.; Kowal, C.; Berlin, R.; Gazaryan, I.G.; Bertini, E.; Zhang, J.; Sanchez-Guerrero, J.; Fragoso-Loyo, H.E.; Volpe, B.T.; Diamond, B.; Huerta, P.T. Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proc. Natl. Acad. Sci. U S A., 2010, 107(43), 18569-18574.
65. Shi, J.; Levinson, D.F.; Duan, J.; Sanders, A.R.; Zheng, Y.; Pe'er, I.; Dudbridge, F.; Holmans, P.A.; Whittemore, A.S.; Mowry, B.J.; Olincy, A.; Amin, F.; Cloninger, C.R.; Silverman, J.M.; Buccola, N.G.; Byerley, W.F.; Black, D.W.; Crowe, R.R.; Oksenberg, J.R.; Mirel, D.B.; Kendler, K.S.; Freedman, R.; Gejman, PV. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature, 2009, 460(7256), 753-757.
66. Stefansson, H.; Ophoff, R.A.; Steinberg, S.; Andreassen, O.A.; Cichon, S.; Rujescu, D.; Werge, T.; Pietiläinen, O.P.; Mors, O.; Mortensen, P.B.; Sigurdsson, E.; Gustafsson, O.; Nyegaard, M.; Tuulio-Henriksson, A.; Ingason, A.; Hansen, T.; Suvisaari, J.; Lönnqvist, J.; Paunio, T.; Børglum, A.D.; Hartmann, A.; Fink-Jensen, A.; Nordentoft, M.; Hougaard, D.; Norgaard-Pedersen, B.; Böttcher, Y.; Olesen, J.; Breuer, R.; Möller, H.J.; Giegling, I.; Rasmussen, H.B.; Timm, S.; Mattheisen, M.; Bitter, I.; Réthelyi, J.M.; Magnusdottir, B.B.; Sigmundsson, T.; Olason, P.; Masson, G.; Gulcher, J.R.; Haraldsson, M.; Fossdal, R.; Thorgeirsson, T.E.; Thorsteinsdottir, U.; Ruggeri, M.; Tosato, S.; Franke, B.; Strengman, E.; Kiemeney, L.A.; GROUP; Melle, I.; Djurovic, S.; Abramova, L.; Kaleda, V.; Sanjuan, J.; de Frutos, R.; Bramon, E.; Vassos, E.; Fraser, G.; Ettinger, U.; Picchioni, M.; Walker, N.; Toulopoulou, T.; Need, A.C.; Ge, D.; Lim Yoon, J.; Shianna, K.V.; Freimer, N.B.; Cantor, R.M.; Murray, R.; Kong, A.; Golimbet, V.; Carracedo, A.; Arango, C.; Costas, J.; Jönsson, E.G.; Terenius, L.; Agartz, I.; Petursson, H.; Nöthen, M.M.; Rietschel, M.; Matthews, P.M.; Muglia, P.; Peltonen, L.; St Clair, D.; Goldstein, D.B.; Stefansson, K.; Collier, D.A.; Genetic Risk and Outcome in Psychosis (GROUP), Kahn, R.S.; Linszen, D.H.; van Os, J.; Wiersma, D.; Bruggeman, R.; Cahn, W.; de Haan, L.; Krabbendam, L.; Myin-Germeys, I. Common variants conferring risk of schizophrenia. Nature, 2009, 460(7256), 744-747.
67. Ripke, S.; Sanders, A.R.; Kendler, K.S.; Levinson, D.F.; Sklar, P.; Holmans, P.A.; Lin, D.Y.; Duan, J.; Ophoff, R.A.; Andreassen, O.A.; Scolnick, E.; Cichon, S.; St Clair, D.; Corvin, A.; Gurling, H.; Werge, T.; Rujescu, D.; Blackwood, D.H.; Pato, C.N.; Malhotra, A.K.; Purcell, S.; Dudbridge, F.; Neale, B.M.; Rossin, L.; Visscher, P.M.; Posthuma, D.; Ruderfer, D.M.; Fanous, A.; Stefansson, H.; Steinberg, S.; Mowry, B.J.;, Golimbet, V.; De Hert, M.; Jönsson, E.G.; Bitter, I.; Pietiläinen, O.P.; Collier, D.A.; Tosato, S.; Agartz, I.; Albus, M.; Alexander, M.; Amdur, R.L.; Amin, F.; Bass, N.; Bergen, S.E.; Black, D.W.; Børglum, A.D.; Brown, M.A.; Bruggeman, R.; Buccola, N.G.; Byerley, W.F.; Cahn, W.; Cantor, R.M.; Carr, V.J.; Catts, S.V.; Choudhury, K.; Cloninger, C.R.; Cormican, P.; Craddock, N.; Danoy, P.A.; Datta, S.; de Haan, L.; Demontis, D.; Dikeos, D.; Djurovic, S.; Donnelly, P.; Donohoe, G.; Duong, L.; Dwyer, S.; Fink-Jensen, A.; Freedman, R.; Freimer, N.B.; Friedl, M.; Georgieva, L.; Giegling, I.; Gill, M.; Glenthøj, B.; Godard, S.; Hamshere, M.; Hansen, M.; Hansen, T.; Hartmann, A.M.; Henskens, F.A.; Hougaard, D.M.; Hultman, C.M.; Ingason, A.; Jablensky, A.V.; Jakobsen, K.D.; Jay, M.; Jürgens, G.; Kahn, R.S.; Keller, M.C.; Kenis, G.; Kenny, E.; Kim, Y.; Kirov, G.K.; Konnerth, H.; Konte, B.; Krabbendam, L.; Krasucki, R.; Lasseter, V.K.; Laurent, C.; Lawrence, J.; Lencz, T.; Lerer, F.B.; Liang, K.Y.; Lichtenstein, P.; Lieberman, J.A.; Linszen, D.H.; Lönnqvist, J.; Loughland, C.M.; Maclean, A.W.; Maher, B.S.; Maier, W.; Mallet, J.; Malloy, P.; Mattheisen, M.; Mattingsdal, M.; McGhee, K.A.; McGrath, J.J.; McIntosh, A.; McLean, D.E.; McQuillin, A.; Melle, I.; Michie, P.T.; Milanova, V.; Morris, D.W.; Mors, O.; Mortensen, P.B.; Moskvina, V.; Muglia, P.; Myin-Germeys, I.; Nertney, D.A.; Nestadt, G.; Nielsen, J.; Nikolov, I.; Nordentoft, M.; Norton, N.; Nöthen, M.M.; O'Dushlaine, C.T.; Olincy, A.; Olsen, L.; O'Neill, F.A.; Orntoft, T.F.; Owen, M.J.; Pantelis, C.; Papadimitriou, G.; Pato, M.T.; Peltonen, L.; Petursson, H.; Pickard, B.; Pimm, J.; Pulver, A.E.; Puri, V.; Quested, D.; Quinn, E.M.; Rasmussen, H.B.; Réthelyi, J.M.; Ribble, R.; Rietschel, M.; Riley, B.P.; Ruggeri, M.; Schall, U.; Schulze, T.G.; Schwab, S.G.; Scott, R.J.; Shi, J.; Sigurdsson, E.; Silverman, J.M.; Spencer, C.C.; Stefansson, K.; Strange, A.; Strengman, E.; Stroup, T.S.; Suvisaari, J.; Terenius, L.; Thirumalai, S.; Thygesen, J.H.; Timm, S.; Toncheva, D.; van den Oord, E.; van Os, J.; van Winkel, R.; Veldink, J.; Walsh, D.; Wang, A.G.; Wiersma, D.; Wildenauer, D.B.; Williams, H.J.; Williams, N.M.; Wormley, B.; Zammit, S.; Sullivan, P.F.; O'Donovan, M.C.; Daly, M.J.; Gejman, P.V.; Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium. Genome-wide association study identifies five new schizophrenia loci. Nat. Genet., 2011, 43(10), 969-976.
68. Kobrynski, L.J.; Sullivan, K.E. Velocardiofacial syndrome, Di-George syndrome: the chromosome 22q11.2 deletion syndromes. Lancet, 2007, 370, 1443-1452.
69. Tison, B.E.; Nicholas, S.K.; Abramson, S.L.; Hanson, I.C.; Paul, M.E.; Seeborg, F.O.; Shearer, W.T.; Perez, M.D.; Noroski, L.M.; Chinen, J. Autoimmunity in a cohort of 130 pediatric patients with partial DiGeorge syndrome. J. Allergy Clin. Immunol., 2011, 128, 1115-1117.
70. Rook, G.A.; Brunet, L.R. Give us this day our daily germs. Biologist (London), 2002, 49, 145-149.
71. Raison, C.L.; Lowry, C.A.; Rook, C.A.W. Inflammation, sanitation, and consternation. Loss of contact with coevolved, tolerogenic micro-organisms and the pathophysiology and treatment of major depression. Arch. Gen. Psychiatry, 2010, 67, 1211-1224.
72. Rhee, S.H.; Pothoulakis, C.; Mayer, E.A. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat. Rev. Gastroenterol. Hepatol., 2009, 6(5), 306-314.
73. Neufeld, K.A.; Foster, J.A. Effects of gut microbiota on the brain: implications for psychiatry. J. Psychiatry Neurosci., 2009, 34(3), 230-1.
74. Neufeld, K.M.; Kang, N.; Bienenstock, J.; Foster, J.A. Reduced anxiety-like behavior and central neurochemical change in germfree mice. Neurogastroenterol. Motil., 2011, 23(3), 255-264
75. Bercik, P.; Verdu, E.F.; Foster, J.A.; Macri, J.; Potter, M.; Huang, X.; Malinowski, P.; Jackson, W.; Blennerhassett, P.; Neufeld, K.A.; Lu, J.; Khan, W.I.; Corthesy-Theulaz, I.; Cherbut, C.; Bergonzelli, G.E.; Collins, S.M. Chronic gastrointestinal inflammation induces anxiety-like behavior and alters central nervous system biochemistry in mice. Gastroenterology, 2010, 139(6), 2102-2112.
76. Bravo, J.A.; Forsythe, P.; Chew, M.V.; Escaravage, E.; Savignac, H.M.; Dinan, T.G.; Bienenstock, J.; Cryan, JF. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc. Natl. Acad. Sci. U S A., 2011, 108(38), 16050-16055.
77. Heijtz, R.D.; Wang, S.; Anuar, F.; Qian, Y.; Björkholm, B.; Samuelsson, A.; Hibberd, M.L.; Forssberg, H.; Pettersson, S. Normal gut microbiota modulates brain development and behavior. Proc. Natl. Acad. Sci. U. S. A., 2011, 108(7), 3047-3052.
78. Gareau, M.G.; Wine, E.; Rodrigues, D.M.; Cho, J.H.; Whary, M.T.; Philpott, D.J.; Macqueen, G.; Sherman, P.M. Bacterial infection causes stress-induced memory dysfunction in mice. Gut, 2011, 60(3), 307-317.
79. Maes, M.; Kubera, M.; Leunis, J.C. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro. Endocrinol. Lett., 2008, 29(1), 117-124.
80. Messaoudi, M.; Lalonde, R.; Violle, N.; Javelot, H.; Desor, D.; Nejdi, A.; Bisson, J.F.; Rougeot, C.; Pichelin, M.; Cazaubiel, M.; Cazaubiel, J.M. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br. J. Nutr., 2011, 105(5), 755-764.
81. Severance, E.G.; Alaedini, A.; Yang, S.; Halling, M.; Gressitt, K.L.; Stallings, C.R.; Origoni, A.E.; Vaughan, C.; Khushalani, S.; Leweke, F.M.; Dickerson, F.B.; Yolken, R.H. Gastrointestinal inflammation and associated immune activation in schizophrenia. Schizophr. Res., 2012, 138(1), 48-53.
82. Samaroo, D.; Dickerson, F.; Kasarda, D.D.; Green, P.H.; Briani, C.; Yolken, R.H.; Alaedini, A. Novel immune response to gluten in individuals with schizophrenia. Schizophr. Res., 2010, 118(1-3), 248-255.
83. Suvisaari, J.M.; Saarni, S.I.; Perälä, J.; Suvisaari, J.V.; Härkänen, T.; Lönnqvist, J.; Reunanen, A. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J. Clin. Psychiatry, 2007, 68(7), 1045-1055.
84. Suvisaari, J.; Perälä, J.; Saarni, S.I.; Härkänen, T.; Pirkola, S.; Joukamaa, M.; Lönnqvist, J.; Reunanen, A. Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey. Eur. Arch. Psychiatry Clin. Neurosci., 2008, 258, 129-136.
85. Saarni, S.E.; Saarni, S.I.; Fogelholm, M.; Heliövaara, M.; Perälä, J.; Suvisaari, J.; Lönnqvist, J. Body composition in psychotic disorders: a general population survey. Psychol. Med., 2009, 39(5), 801-810.
86. De Hert, M.; Correll, C.U.; Bobes, J.; Cetkovich-Bakmas, M.; Cohen, D.; Asai, I.; Detraux, J.; Gautam, S.; Möller, H.J.; Ndetei, D.M.; Newcomer, J.W.; Uwakwe, R.; Leucht, S. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry, 2011, 10(1), 52-77.
87. Mitchell, A.J.; Vancampfort, D.; Sweers, K.; van Winkel, R.; Yu, W.; De Hert, M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--A systematic review and meta-analysis. Schizophr. Bull., 2013, 39(2), 306-318.
88. Leboyer, M.; Soreca, I.; Scott, J.; Frye, M.; Henry, C.; Tamouza, R.; Kupfer, D.J. Can bipolar disorder be viewed as a multi-system inflammatory disease? J. Affect. Disord., 2012, 141(1), 1-10.
89. Pradhan, A.D.; Manson, J.E.; Rifai, N.; Buring, J.E.; Ridker, P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes. JAMA, 2001, 286, 327-334.
90. Hajer, G.R.; van Haeften, T.W.; Visseren, F.L.J. Adipose tissue dysfunction in obesity, diabetes, and vascular disease. Eur. Heart J., 2008, 29, 2959-2971.
91. Després, J.P.; Lemieux, I. Abdominal obesity and metabolic syndrome. Nature, 2006, 444(7121), 881-887.
92. Sopori, M. Effects of cigarette smoke on the immune system. Nat. Rev. Immunol. 2002, 2, 372-377.
93. Cook, R.T. Alcohol abuse, alcoholism, and damage to the immune system-a review. Alcohol. Clin. Exp. Res., 1998, 22, 1927-1942.
94. Schrager, M.A.; Metter, E.J.; Simonsick, E.; Ble, A.; Bandinelli, S.; Lauretani, F.; Ferrucci, L. Sarcopenic obesity and inflammation in the InCHIANTI study. J. Appl. Physiol. 2007, 102, 919-925.
95. Ruiz, J.R.; Ortega, F.B.; Wärnberg, J.; Moreno, L.A.; Carrero, J.J.; Gonzalez-Gross, M.; Marcos, A.; Gutierrez, A.; Sjöström, M. Inflammatory proteins and muscle strength in adolescents. The AVENA study. Arch. Pediatr. Adolesc. Med., 2008, 162, 462-468.
96. Packard, C.J.; Bezlyak, V.; McLean, J.S.; Batty, G.D.; Ford, I.; Burns, H.; Cavanagh, J.; Deans, K.A.; Henderson, M.; McGinty, A.; Millar, K.; Sattar, N.; Shiels, P.G.; Velupillai, Y.N.; Tannahill, C. Early life socioeconomic adversity is associated in adult life with chronic inflammation, carotid atherosclerosis, poorer lung function and decreased cognitive performance: a cross-sectional, population-based study. BMC Public Health, 2011, 11, 42.
97. Friedman, E.M.; Herd, P. Income, education, and inflammation: differential associations in a national probability sample (The MIDUS study). Psychosom. Med., 2010, 72, 290-300.
98. Meyer, J.M.; McEvoy, J.P.; Davis, V.G.; Goff, D.C.; Nasrallah, H.A.; Davis, S.M.; Hsiao, J.K.; Swartz, M.S.; Stroup, T.S.; Lieberman, J.A. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol. Psychiatry, 2009, 66(11), 1013-1022.
99. Lakoski, S.G.; Cushman, M.; Palmas, W.; Blumenthal, R.; D'Agostino, R.B. Jr.; Herrington, D.M. The relationship between blood pressure and C-reactive protein in the Multi-Ethnic Study of Atherosclerosis (MESA). J. Am. Coll. Cardiol., 2005, 46, 1869-1874.
100. Cartier, A.; Bergeron, J.; Poirier, P.; Almeras, N.; Tremblay, A.; Lemieux, I.; Despres, J.P. Increased plasma interleukin-1 receptor antagonist levels in men with visceral obesity. Ann. Med., 2009, 41, 471-478.
101. Luotola, K.; Pietilä, A.; Alanne, M.; Lanki, T.; Loo, B.M.; Jula, A.; Perola, M.; Peters, A.; Zeller, T.; Blankenberg, S.; Salomaa, V.; Health 2000, FINRISK97, and AIRGENE Study Groups. Genetic variation of the interleukin-1 family and nongenetic factors determining the interleukin-1 receptor antagonist phenotypes. Metabolism, 2010, 59, 1520-1527.
102. Steptoe, A.; Hamer, M.; Chida, Y. The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain Behav. Immun., 2007, 21, 901-912.
103. Freier, E.; Weber, C.S.; Nowottne, U.; Horn, C.; Bartels, K.; Meyer, S.; Hildebrandt, Y.; Luetkens, T.; Cao, Y.; Pabst, C.; Muzzulini, J.; Schnee, B.; Brunner-Weinzierl, M.C.; Marangolo, M.; Bokemeyer, C.; Deter, H.C.; Atanackovic, D. Decrease of CD4(+)FOXP3(+) T regulatory cells in the peripheral blood of human subjects undergoing a mental stressor. Psychoneuroendocrinology., 2010, 35(5), 663-673.
104. Myin-Germeys, I.; Delespaul, P.; van Os J. Behavioural sensitization to daily life stress in psychosis. Psychol. Med., 2005, 35(5), 733-741.
105. Collip, D.; Nicolson, N.A.; Lardinois, M.; Lataster, T.; van Os, J.; Myin-Germeys, I.; G.R.O.U.P. Daily cortisol, stress reactivity and psychotic experiences in individuals at above average genetic risk for psychosis. Psychol. Med., 2011, 41(11), 2305-2315.
106. Walker, E.F.; Brennan, P.A.; Esterberg, M.; Brasfield, J.; Pearce, B.; Compton, M.T. Longitudinal changes in cortisol secretion and conversion to psychosis in at-risk youth. J. Abnorm. Psychol., 2010, 119(2), 401-408.
107. Mondelli, V.; Dazzan, P.; Hepgul, N.; Di Forti, M.; Aas, M.; D'Albenzio, A.; Di Nicola, M.; Fisher, H.; Handley, R.; Marques, T.R.; Morgan, C.; Navari, S.; Taylor, H.; Papadopoulos, A.; Aitchison, K.J.; Murray, R.M.; Pariante, C.M. Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatment. Schizophr. Res., 2010, 116(2-3), 234-242.
108. Garner, B.; Phassouliotis, C.; Phillips, L.J.; Markulev, C.; Butselaar, F.; Bendall, S.; Yun, Y.; McGorry, P.D. Cortisol and dehydroepiandrosterone-sulphate levels correlate with symptom severity in first-episode psychosis. J. Psychiatr. Res., 2011, 45(2), 249-255.
109. Potvin, S.; Stip, E.; Sepehry, A.A.; Gendron, A.; Bah, R.; Kouassi, E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry, 2008, 63, 801-808.
110. Bebbington, P.E.; Bhugra, D.; Brugha, T.; Singleton, N.; Farrell, M.; Jenkins, R.; Lewis, G.; Meltzer, H. Psychosis, victimisation and childhood disadvantage: evidence from the second British National Survey of Psychiatric Morbidity. Br. J. Psychiatry, 2004, 185, 220-226.
111. Bebbington, P.; Jonas, S.; Kuipers, E.; King, M.; Cooper, C.; Brugha, T.; Meltzer, H.; McManus, S.; Jenkins, R. Childhood sexual abuse and psychosis: data from a cross-sectional national psychiatric survey in England. Br. J. Psychiatry, 2011, 199(1), 29-37.
112. Varese, F.; Smeets, F.; Drukker, M.; Lieverse, R.; Lataster, T.; Viechtbauer, W.; Read, J.; van Os, J.; Bentall, R.P. Childhood adversities increase the risk of psychosis: A meta-analysis of patientcontrol, prospective-and cross-sectional cohort studies. Schizophr. Bull., 2012, 38(4), 661-671.
113. Danese, A.; Moffitt, T.E.; Harrington, H.; Milne, B.J.; Polanczyk, G.; Pariante, C.M.; Poulton, R.; Caspi, A. Adverse childhood experiences and adult risk factors for age-related disease: depression, inflammation, and clustering of metabolic risk markers. Arch. Pediatr. Adolesc. Med., 2009, 163(12), 1135-1143.
114. Kiecolt-Glaser, J.K.; Gouin, J.P.; Weng, N.P.; Malarkey, W.B.; Beversdorf, D.Q.; Glaser, R. Childhood adversity heightens the impact of later-life caregiving stress on telomere length and inflammation. Psychosom. Med., 2011, 73(1), 16-22.
115. Miller, G.E.; Cole, S.W. Clustering of depression and inflammation in adolescents previously exposed to childhood adversity. Biol. Psychiatry, 2012, 72(1), 34-40.
116. Carpenter, L.L.; Gawuga, C.E.; Tyrka, A.R.; Lee, J.K.; Anderson, G.M.; Price, L.H. Association between plasma IL-6 response to acute stress and early-life adversity in healthy adults. Neuropsychopharmacology, 2010, 35, 2617-23.
117. Hepgul, N.; Pariante, C.M.; Dipasquale, S.; Diforti, M.; Taylor, H.; Marques, T.R.; Morgan, C.; Dazzan, P.; Murray, R.M.; Mondelli, V. Childhood maltreatment is associated with increased body mass index and increased C-reactive protein levels in first-episode psychosis patients. Psychol. Med., 2012, 42(9), 1893-1901.
118. Bian, Q.; Kato, T.; Monji, A.; Hashioka, S.; Mizoguchi, Y.; Horikawa, H.; Kanba, S. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32(1), 42-48.
119. Shaltiel, G.; Chen, G.; Manji, H.K. Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. Curr. Opin. Pharmacol. 2007, 7(1), 22-26.
120. Hunsberger, J.; Austin, D.R.; Henter, I.D.; Chen, G. The neurotrophic and neuroprotective effects of psychotropic agents. Dialogues Clin. Neurosci., 2009, 11(3), 333-348.
121. Goldstein, B.I.; Kemp, D.E.; Soczynska, J.K.; McIntyre, R.S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J. Clin. Psychiatry, 2009, 70, 1078-1090.
122. Porcelli, S.; Drago, A.; Fabbri, C.; Serretti, A. Mechanisms of antidepressant action: an integrated dopaminergic perspective. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2011, 35(7), 1532-1543.
123. Citrome, L. Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence? Expert Rev. Neurother., 2009, 9, 55-71.
124. Torrey, E.F.; Davis, J.M. Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas. Clin. Schizophr. Relat. Psychoses, 2012, 5(4), 208-216.
125. Sepehry, A.A.; Potvin, S.; Elie, R.; Stip, E. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J. Clin. Psychiatry, 2007, 68, 604-610.
126. Phan, S.V.; Kreys, T.J. Adjunct mirtazapine for negative symptoms of schizophrenia. Pharmacotherapy, 2011, 31(10), 1017-1030.
127. Sommer, I.E.; de Witte, L.; Begemann, M.; Kahn, R.S. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? a meta-analysis. J. Clin. Psychiatry, 2012, 73(4), 414-419.
128. Laan, W.; Grobbee, D.E.; Selten, J.P.; Heijnen, C.J.; Kahn, R.S.; Burger, H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry, 2010, 71, 520-527.
129. Nery, F.G.; Monkul, E.S.; Hatch, J.P.; Fonseca, M.; Zunta-Soares, G.B.; Frey, B.N.; Bowden, C.L.; Soares, J.C. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum. Psychopharmacol., 2008, 23, 87-94.
130. Phelan, K.M.; Mosholder, A.D.; Lu, S. Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. J. Clin. Psychiatry, 2003, 64(11), 1328-1334.
131. Dean, O.; Giorlando, F.; Berk, M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J. Psychiatry Neurosci., 2011, 36(2), 78-86.
132. Berk, M.; Copolov, D.; Dean, O.; Lu, K.; Jeavons, S.; Schapkaitz, I.; Anderson-Hunt, M.; Judd, F.; Katz, F.; Katz, P.; Ording-Jespersen, S.; Little, J.; Conus, P.; Cuenod, M.; Do, K.Q.; Bush, A.I. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biol. Psychiatry, 2008, 64(5), 361-368.
133. Berk, M.; Copolov, D.L.; Dean, O.; Lu, K.; Jeavons, S.; Schapkaitz, I.; Anderson-Hunt, M.; Bush, A.I. N-acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial. Biol. Psychiatry, 2008, 64(6), 468-475.
134. Berk M, Dean O, Cotton SM, Gama CS, Kapczinski F, Fernandes BS, Kohlmann K, Jeavons S, Hewitt K, Allwang C, Cobb H, Bush AI, Schapkaitz I, Dodd S, Malhi GS. The efficacy of Nacetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J. Affect. Disord., 2011, 135(1-3), 389-394.
135. Fusar-Poli, P.; Berger, G. Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies. J. Clin. Psychopharmacol., 2012, 32(2), 179-185.
136. Preti, A.; Cella, M. Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness. Schizophr. Res., 2010, 123(1), 30-36.
137. Amminger, G.P.; Schäfer, M.R.; Papageorgiou, K.; Klier, C.M.; Cotton, S.M.; Harrigan, S.M.; Mackinnon, A.; McGorry, P.D.; Berger, G.E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry, 2010, 67(2), 146-154.
138. López-Alarcón, M.; Martínez-Coronado, A.; Velarde-Castro, O.; Rendón-Macías, E.; Fernández, J. Supplementation of n3 longchain polyunsaturated fatty acid synergistically decreases insulin resistance with weight loss of obese prepubertal and pubertal children. Arch. Med. Res., 2011, 42, 502-508.
139. Marx, C.E.; Bradford, D.W.; Hamer, R.M.; Naylor, J.C.; Allen, T.B.; Lieberman, J.A.; Strauss, J.L.; Kilts, J.D. Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. Neuroscience, 2011, 191, 78-90.
140. Maninger, N.; Wolkowitz, O.M.; Reus, V.I.; Epel, E.S.; Mellon, S.H. Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). Front. Neuroendocrinol., 2009, 30, 65-91.
141. Ritsner, M.S.; Strous, R.D. Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA. J. Psychiatr. Res., 2010, 44(2), 75-80.
142. Strous, R.D.; Stryjer, R.; Maayan, R.; Gal, G.; Viglin, D.; Katz, E.; Eisner, D.; Weizman, A. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Psychoneuroendocrinology, 2007, 32(2), 96-105.
143. Dean, O.M.; Data-Franco, J.; Giorlando, F.; Berk, M. Minocycline: therapeutic potential in psychiatry. CNS Drugs., 2012, 26(5), 391-401.
144. Chaudhry, I.B.; Hallak, J.; Husain, N.; Minhas, F.A.; Stirling, J.; Richardson, P.; Dursun, S.; Dunn, G.; Deakin, B. Minocycline benefits negative symptoms in early schizophrenia; a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J. Psychopharmacol., 2012, 26(9), 1185-1193.
145. Ritsner, M.S.; Miodownik, C.; Ratner, Y.; Shleifer, T.; Mar, M.; Pintov, L.; Lerner, V. L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebocontrolled, 2-center study. J. Clin. Psychiatry, 2011, 72(1), 34-42.
146. Wood, S.J.; Yung, A.R.; McGorry, P.D.; Pantelis, C. Neuroimaging and treatment evidence for clinical staging in psychotic disorders: from the at-risk mental state to chronic schizophrenia. Biol. Psychiatry, 2011, 70, 619-625.
147. Schwarcz, R.; Bruno, J.P.; Muchowski, P.J.; Wu, H.Q. Kynurenines in the mammalian brain: when physiology meets pathology. Nat. Rev. Neurosci., 2012, 13(7), 465-477.
148. Müller, N.; Schwarz, M.J. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol. Psychiatry, 2007, 12(11), 988-1000.
149. Maes, M.; Yirmyia, R.; Noraberg, J.; Brene, S.; Hibbeln, J.; Perini, G.; Kubera, M.; Bob, P.; Lerer, B.; Maj, M. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab. Brain Dis., 2009, 24, 27-53.
150. Kempermann, G.; Fabel, K.; Ehninger, D.; Babu, H.; Leal-Galicia, P.; Garthe, A.; Wolf, S.A. Why and how physical activity promotes experience-induced brain plasticity. Front. Neurosci., 2010, 4, 189.
151. Anderson, G.; Maes, M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metab. Brain. Dis., 2012, 27(2), 113-119.
152. Berk, M.; Kapczinski, F.; Andreazza, A.C.; Dean, O.M.; Giorlando, F.; Maes, M.; Yücel, M.; Gama, C.S.; Dodd, S.; Dean, B.; Magalhães, P.V.; Amminger, P.; McGorry, P.; Malhi, G.S. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev., 2011, 35(3), 804-817.
153. Mortensen, P.B.; Pedersen, C.B.; Hougaard, D.M.; Nørgaard-Petersen, B.; Mors, O.; Børglum, A.D.; Yolken, R.H. A Danish National Birth Cohort study of maternal HSV-2 antibodies as a risk factor for schizophrenia in their offspring. Schizophr Res., 2010, 122(1-3), 257-263.
154. Nielsen, P.R.; Laursen, T.M.; Mortensen, P.B. Association between parental hospital-treated infection and the risk of schizophrenia in adolescence and early adulthood. Schizophr. Bull., 2013, 39(1), 230-237.
155. de Jager, W.; Bourcier, K.; Rijkers, G.T.; Prakken, B.J.; Seyfert-Margolis, V. Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunol., 2009, 10, 52.